Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Morgane Rolland

Showing results (101-110 of 120) with videos related to

Pageof 12
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|January 19, 2024
Prevention efficacy of the broadly neutralizing antibody VRC01 depends on HIV-1 envelope sequence featuresMichal Juraska, Hongjun Bai, Allan C deCamp, et al.
Plos Pathogens|September 15, 2017
Correction: Rare HIV-1 transmitted/founder lineages identified by deep viral sequencing contribute to rapid shifts in dominant quasispecies during acute and early infectionGustavo H Kijak, Eric Sanders-Buell, Agnes-Laurence Chenine, et al.
Mbio|September 9, 2025
Bayesian estimation of HIV acquisition dates for prevention trialsRaabya Rossenkhan, Elena E Giorgi, Danica Shao, et al.
Nature|September 11, 2012
Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2Morgane Rolland, Paul T Edlefsen, Brendan B Larsen, et al.
Nature Communications|April 3, 2026
Influence of the broadly neutralizing antibody VRC01 on HIV breakthrough virus populations in antibody-mediated prevention trialsCarolyn Williamson, Chivonne Moodley, Craig A Magaret, et al.
Nature Communications|February 3, 2023
Shark nanobodies with potent SARS-CoV-2 neutralizing activity and broad sarbecovirus reactivityWei-Hung Chen, Agnes Hajduczki, Elizabeth J Martinez, et al.
Structure (London, England : 1993)|December 29, 2023
Antibody targeting of conserved sites of vulnerability on the SARS-CoV-2 spike receptor-binding domainRajeshwer S Sankhala, Vincent Dussupt, Wei-Hung Chen, et al.
Cell Reports|August 10, 2023
Zika-specific neutralizing antibodies targeting inter-dimer envelope epitopesRajeshwer S Sankhala, Vincent Dussupt, Gina Donofrio, et al.
Plos One|November 18, 2017
Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120Allan C deCamp, Morgane Rolland, Paul T Edlefsen, et al.
Biorxiv : the Preprint Server for Biology|July 17, 2025
Influence of the broadly neutralizing antibody VRC01 on HIV breakthrough virus populations in antibody-mediated prevention trialsCarolyn Williamson, Chivonne Moodley, Craig A Magaret, et al.
Pageof 12

Showing results (101-110 of 120) with videos related to

Sort By:
Pageof 12
Proceedings of the National Academy of Sciences of the United States of America|January 19, 2024
Prevention efficacy of the broadly neutralizing antibody VRC01 depends on HIV-1 envelope sequence featuresMichal Juraska, Hongjun Bai, Allan C deCamp, et al.
Plos Pathogens|September 15, 2017
Correction: Rare HIV-1 transmitted/founder lineages identified by deep viral sequencing contribute to rapid shifts in dominant quasispecies during acute and early infectionGustavo H Kijak, Eric Sanders-Buell, Agnes-Laurence Chenine, et al.
Mbio|September 9, 2025
Bayesian estimation of HIV acquisition dates for prevention trialsRaabya Rossenkhan, Elena E Giorgi, Danica Shao, et al.
Nature|September 11, 2012
Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2Morgane Rolland, Paul T Edlefsen, Brendan B Larsen, et al.
Nature Communications|April 3, 2026
Influence of the broadly neutralizing antibody VRC01 on HIV breakthrough virus populations in antibody-mediated prevention trialsCarolyn Williamson, Chivonne Moodley, Craig A Magaret, et al.
Nature Communications|February 3, 2023
Shark nanobodies with potent SARS-CoV-2 neutralizing activity and broad sarbecovirus reactivityWei-Hung Chen, Agnes Hajduczki, Elizabeth J Martinez, et al.
Structure (London, England : 1993)|December 29, 2023
Antibody targeting of conserved sites of vulnerability on the SARS-CoV-2 spike receptor-binding domainRajeshwer S Sankhala, Vincent Dussupt, Wei-Hung Chen, et al.
Cell Reports|August 10, 2023
Zika-specific neutralizing antibodies targeting inter-dimer envelope epitopesRajeshwer S Sankhala, Vincent Dussupt, Gina Donofrio, et al.
Plos One|November 18, 2017
Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120Allan C deCamp, Morgane Rolland, Paul T Edlefsen, et al.
Biorxiv : the Preprint Server for Biology|July 17, 2025
Influence of the broadly neutralizing antibody VRC01 on HIV breakthrough virus populations in antibody-mediated prevention trialsCarolyn Williamson, Chivonne Moodley, Craig A Magaret, et al.
Pageof 12